Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk
Background As observed in tobacco‐associated carcinogenesis, genetic factors such as the polymorphic metabolic/oxidative enzyme myeloperoxidase (MPO) could modulate individual susceptibility to asbestos‐associated carcinogenesis. Methods RFLP‐PCR analysis identified the MPO genotypes in 375 Caucasia...
Saved in:
Published in | American journal of industrial medicine Vol. 42; no. 1; pp. 29 - 37 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Wiley Subscription Services, Inc., A Wiley Company
01.07.2002
Wiley-Liss |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
As observed in tobacco‐associated carcinogenesis, genetic factors such as the polymorphic metabolic/oxidative enzyme myeloperoxidase (MPO) could modulate individual susceptibility to asbestos‐associated carcinogenesis.
Methods
RFLP‐PCR analysis identified the MPO genotypes in 375 Caucasian lung cancer cases and 378 matched controls. An epidemiological interview elicited detailed information regarding smoking history and occupational history and exposures.
Results
Asbestos exposure was associated with a significantly elevated risk estimate (OR = 1.45; 95% CI 1.04–2.02). On stratified analysis, we found the MPO genotypes modified the effect of asbestos exposure on lung cancer risk. Specifically, G/G carriers who were exposed to asbestos had an odds ratio (OR) of 1.72 (95% CI; 1.09–2.66), while A‐allele carriers (G/A + A/A) exposed to asbestos exhibited a reduced OR of 0.89 (95% CI; 0.56–1.44). The OR was further reduced to 0.73 (0.49–1.06) for A‐allele carriers not exposed to asbestos. A similar trend was observed for the joint effects between the MPO genotypes and pack‐years smoking. Next, all three risk factors (MPO genotypes, asbestos exposure, and smoking) were analyzed simultaneously for joint effects. Heavy smokers with the G/G genotype and a history of asbestos exposure demonstrated a statistically significant elevated risk estimate (OR = 2.19; 95% CI 1.16–4.11), while the A‐allele carriers with the same exposure profile were at a lower risk for lung cancer (OR = 1.18; 95% CI 0.58–2.38). The A‐allele genotypes demonstrated similar protective effects for the other three exposure profiles.
Conclusions
For a similar level of exposure to established carcinogens, individuals with the MPO A‐allele genotypes appear to have a reduced risk of lung cancer. Am. J. Ind. Med. 42:29–37, 2002. © 2002 Wiley‐Liss, Inc. |
---|---|
Bibliography: | istex:9FE8317F2A894D73A44BA0B50E2CE22A2C1526FE ark:/67375/WNG-3SKMMP9H-S ArticleID:AJIM10084 NCI - No. CA 55769; No. CA 74880 NCI (cancer prevention fellowship) - No. R25 CA57730 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ISSN: | 0271-3586 1097-0274 |
DOI: | 10.1002/ajim.10084 |